Press Releases from GBI Research (17 total)
Diabetes and obesity therapeutics market will more than double to $163.2 billion …
Report Title: Global Diabetes and Obesity Drugs Market to 2022
The global market for diabetes mellitus and obesity is set to rise from $70.8 billion in 2015 to $163.2 billion by 2022, at a strong compound annual growth rate of 12.7%.
Callum Dew, Associate Analyst for GBI Research, explains: “Recent approvals and pipeline products that are expected to be key players during the forecast period include Tresiba (insulin degludec), Invokana (canagliflozin)…
Glioblastoma market set for strong innovation, with 120 first-in-class programs
Glioblastoma, a particularly aggressive form of brain tumor, has a promising treatment pipeline, with 120 first-in-class programs acting on 86 first-in-class molecular targets. Adam Bradbury, MSc, Associate Analyst for GBI Research, explains: “Pipeline innovation has far-reaching strategic implications for all market participants as, despite the high attrition rate in glioblastoma, it is highly likely that many of the numerous first-in-class products, a number of which are supported by promising preclinical…
Global drug delivery technologies market will reach $26 billion by 2020
The global market for drug delivery technologies will rise from $20 billion in 2015 to around $26 billion by 2020. Deekshita Allavarapu, Analyst for GBI Research, states: “The size of the US market was estimated to be $6.2 billion in 2015 and is projected to grow at a compound annual growth rate (CAGR) of 4.3% from 2010 to reach $7.7 billion in 2020.
“The US drug delivery technologies market will continue…
Increased diagnoses of hemophilia A and B will drive Asia-Pacific market growth …
The hemophilia A and B markets in the Asia-Pacific (APAC) region are forecast to expand from $444.9 million and $76.3 million in 2015 to $699.1 million and $112.9 million by 2022, representing compound annual growth rates of 6.7% and 5.8%, respectively.
Gayathri Kanika, Analyst for GBI Research, notes: “One of the most pressing unmet needs in the hemophilia space is for a treatment to address inhibitor development, particularly in those…
Cardiovascular disease market set to grow very slowly to $146.4 billion by 2022
The cardiovascular disease market, which includes hypertension, dyslipidemia, and thrombotic events, is set to grow from $129.2 billion in 2015 to $146.4 billion by 2022, at a very modest compound annual growth rate of 1.8%.
Thomas Jarratt, Associate Analyst for GBI Research, explains: “Unlike AstraZeneca, some key players will experience revenue growth resulting from the introduction of new products to market. In particular, Sanofi’s Praluent (alirocumab) is expected to help mitigate…
Gastrointestinal drugs market to hit $48.4 billion by 2022 as biologic products …
The market size for gastrointestinal therapeutics is set to grow from $35.7 billion in 2015 to $48.4 billion by 2022, representing a compound annual growth rate of 4.45%.
Jennifer Goossens, Associate Analyst for GBI Research, explains: “Recently approved products include Intercept’s Ocaliva, for the treatment of primary biliary cirrhosis, and Takeda’s Takecab for acid-related diseases such as gastroesophageal reflux disease – which are both forecast to generate annual revenue of over…
Cancer vaccines market will soar to $7.5 billion by 2022, says GBI Research
The cancer vaccines market is set to almost triple from $2.5 billion in 2015 to $7.5 billion by 2022, representing a strong compound annual growth rate of 16.93%.
Adam Bradbury, Associate Analyst for GBI Research, explains: “The cancer vaccines space will see such impressive growth over next decade for a number of reasons. There is a fairly large cancer vaccine pipeline, with over 1,200 products being developed, accounting for almost 17%…
Global neurodegenerative drugs market set to hit $45 billion by 2022
Neurodegenerative disorders market, which covers Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, and multiple sclerosis (MS), is set to grow from $27.2 billion in 2015 to $45 billion by 2022, at a compound annual growth rate of 7.42%.
Qaisrah Khalid, Analyst for GBI Research, explains: “There is a large pharmaceutical pipeline for neurodegenerative disorders, consisting of approximately 1,494 products in active development. The majority of pipeline products are…
Cancer immunotherapies space to witness extraordinary growth, reaching $75.8 bil …
Report Title: Global Cancer Immunotherapies Market to 2022.
The market size for cancer immunotherapies is expected to grow more than fourfold from $16.9 billion in 2015 to $75.8 billion by 2022, representing a rapid compound annual growth rate (CAGR) of 23.9%
Yasser Mushtaq, Senior Analyst for GBI Research, explains: “Although the cancer immunotherapy pipeline is clearly strong, a significant proportion is made up of early-stage products, namely those from the Discovery stage…
Low innovation in hepatitis C therapies means significant unmet needs remain
Although recent years have seen a revolution in the hepatitis C space, as interferon-free direct-acting antiviral (DAA) combination therapies have started replacing interferon-based therapies, a number of considerable unmet needs remain.
Jennifer Goossens, Associate Analyst for GBI Research, explains: Hepatitis C virus resistance to DAAs may also be a cause for concern, as the development of selection pressure by the host immune system in combination with DAA therapy may lead to…
Ophthalmology’s diverse pipeline could rejuvenate previously stagnant therapy …
Report Title: Frontier Pharma: Ophthalmology Therapeutics.
The ophthalmology market has experienced relatively little advancement in recent years and, with large unmet needs remaining in this area, there are strong opportunities for more products to enter the treatment space, according to business intelligence provider GBI Research.
Dominic Trewartha, Managing Analyst for GBI Research, explains: “The ophthalmology pipeline contains a diverse range of molecular targets and no single target dominates by any clear…
Asia-Pacific gastric cancer market set to experience strong growth to $2.7 billi …
Report Title: Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies.
The Asia-Pacific (APAC) gastric cancer market is set to rise from $1.3 billion in 2015 to $2.7 billion by 2022, at a strong compound annual growth rate of 11.4%, according to business intelligence provider GBI Research.
Gayathri Kanika, Analyst for GBI Research, states: “In line with improved diagnosis rates, the…
Low innovation in hepatitis C therapies means significant unmet needs remain, sa …
Report Title: Frontier Pharma: Hepatitis C – Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations
Although recent years have seen a revolution in the hepatitis C space, as interferon-free direct-acting antiviral (DAA) combination therapies have started replacing interferon-based therapies, a number of considerable unmet needs remain.
Jennifer Goossens, Associate Analyst for GBI Research, explains: “Hepatitis C virus resistance to DAAs may also be a cause for concern,…
Global Viral Infections Market to Reach $117.6 Billion by 2021
Report Title: Global Viral Infections Market to 2021 – Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics
Fiona Chisholm, Analyst for GBI Research, states that: “Some 1,848 pipeline products are specifically in development for the treatment of viral infections, accounting for a sizeable proportion of the infectious diseases pipeline. Among these products, HIV has the most at an active stage of development, with 419, followed by…
Asia-Pacific anti-hypertensive therapeutics market to hit $27 billion by 2022, d …
Report Title: Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 – Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline
The market for anti-hypertensive therapeutics across the five Asia-Pacific (APAC) countries of India, China, Australia, South Korea, and Japan, is set to grow from $19.1 billion in 2015 to $27 billion by 2022, at a compound annual growth rate of 5.1%.
Gautam Arora, Analyst for GBI Research, explains: “The anti-hypertensive pipeline consists…
Currently underserved melanoma therapeutics space offers promising pipeline, wit …
Ophthalmological disorders market, which is set to almost double from $13.7 billion in 2015 to $26 billion by 2022 at a compound annual growth rate (CAGR) of 9.48%, will see the entry of a range of new companies over the forecast period as the treatment space is transformed by patent expiries and new product entrants.
Callum Dew, Associate Analyst for GBI Research, explains: “Despite a high attrition rate in oncology…
Antibacterial drugs market will hit $35.6 billion by 2022, as efforts increase t …
The antibacterial drugs market is set to grow from $27.7 billion in 2015 to $35.6 billion by 2022, representing a compound annual growth rate of 3.97%, according to business intelligence provider GBI Research.
The company’s latest report states that emerging companies and the approvals of new products will drive this growth, along with the continued success of the established marketed products Infanrix, which vaccinates against diphtheria, tetanus and pertussis, and Augmentin,…
